Schrödinger

120 West 45th Street
17th Floor
New York
NY
10036-4041
United States

Tel: 503-299-1150

Website: https://www.schrodinger.com/careers

About Schrödinger

Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services to accelerate and increase the efficiency of drug discovery for its clients, which include all major pharmaceutical and biotechnology companies worldwide, as well as leading materials science researchers. Schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and was a co-founder of leading biotech companies including Nimbus Therapeutics, Morphic Therapeutic, and others. Through significant long-term investments in basic research, Schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science.

A great company is made up of great people, and Schrödinger is no exception. Whether you’re in Administration, Sales, Finance, Law, Engineering, IT, or Science, we are always on the lookout for exceptional candidates who can join us and make our team stronger. You will find Schrödinger to be a dynamic, energetic, and fast-paced place to work, where you get to interact with some of the smartest and hardest working people you’ll ever meet. If you’ve ever had a curiosity about science, and how science can improve people’s lives, then there’s no
better place to be than Schrödinger.

Stock Exchange: NASDAQ

Stock Symbol: SDGR

70 articles with Schrödinger

Schrödinger to Present at Two Investor Healthcare Conferences in June

5/25/2021

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will provide a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021, at 3:00 p.m. ET.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - May 19, 2021

5/19/2021

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, reported that on May 15, 2021, the company granted non-statutory stock options to purchase an aggregate of 22,775 shares of the company’s common stock to 11 newly-hired employees.
Schrödinger Reports First Quarter 2021 Financial Results and Provides Company Update

5/11/2021

First quarter total revenue of $32.1 million, up 23 percent year-over-year; Software revenue of $26.3 million, up 11 percent year-over-year
Schrödinger to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

5/4/2021

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that management will provide a corporate overview at the Bank of America Securities 2021 Virtual Healthcare Conference. The presentation will take place virtually on Tuesday, May 11, 2021, at 3:30 pm. ET.
Schrödinger to Host Conference Call to Discuss First Quarter 2021 Financial Results

4/27/2021

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Tuesday, May 11, 2021, at 8:30 a.m. ET to discuss first quarter 2021 financial results and provide a general business update.
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

4/16/2021

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today reported that on April 13, 2021, the company granted non-statutory stock options to purchase an aggregate of 7,450 shares of the company’s common stock to three newly-hired employees.
Schrödinger Reports Preclinical Data on Novel, Selective CDC7 Inhibitors Presented at American Association for Cancer Research Annual Meeting

4/12/2021

– Data highlight continued progress across internal pipeline; Company continues to plan for multiple IND-enabling studies in 2021 and up to three IND applications in 2022 – – Schrödinger to provide an overview of CDC7, MALT1 and Wee1 programs during a webcast today at 10:00 a.m. ET –
Schrödinger to Participate in BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery

4/9/2021

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrödinger, will participate in a panel during the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery. The panel will take place virtually on Friday, April 16, at 10:00 a.m. ET.
Schrödinger to Host Webcast in Conjunction with Presentation of Preclinical Data for Its CDC7 Program at Virtual AACR Annual Meeting

3/30/2021

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a webcast to review the preclinical data being presented from its CDC7 program during a virtual poster session at the upcoming American Association for Cancer Research (AACR) Annual Meeting.
Schrödinger to Participate in Credit Suisse 2021 Healthcare Innovators Series: The Intersection of Drug Discovery, Drug Development and Artificial Intelligence

3/17/2021

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrödinger, will participate in a panel during the Credit Suisse 2021 Healthcare Innovators Series:
Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2020 and Provides Outlook for 2021

3/4/2021

Total revenue of $108.1 million in 2020, up 26 percent year-over-year Software revenue of $92.5 million in 2020, up 39 percent year-over-year Strong financial position enables continued investment in advancing the science underlying Schrödinger’s computational platform Internal pipeline progressing, with plans to submit investigational new drug applications in 2022 Conference call today, Thursday, March 4, at 8:30 a.m. ET
Schrödinger to Host Conference Call to Discuss Fourth Quarter and Year-End 2020 Financial Results

2/18/2021

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that it will host a conference call and webcast on Thursday, March 4, 2021, at 8:30 a.m. ET to discuss fourth quarter and year-end 2020 financial results and provide a general business update.
Schrödinger Presents Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

12/7/2020

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, presented preclinical data from its wholly-owned MALT1 inhibitor program in B-cell lymphomas at the virtual 62nd American Society of Hematology Annual Meeting.
Schrödinger, Inc. Reports Third Quarter 2020 Financial Results and Business Update

11/12/2020

Total revenue of $25.8 million, up 29% year-over-year; Software revenue of $22.9 million, up 42% year-over-year Raised $325.6 million net proceeds in equity financing Presenting data on our MALT 1 inhibitor program at the American Society of Hematology (ASH) Annual Meeting & Exposition Conference call today, Thursday, Nov. 12, 2020 at 8:30 a.m. ET
Schrödinger to Present at Upcoming Investor Conferences - Nov 10, 2020

11/10/2020

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced that members of the management team will participate in the upcoming virtual investor conferences in November and December.
Schrödinger to Present Data from Its MALT1 Inhibitor Program at the American Society of Hematology (ASH) 2020 Annual Meeting

11/5/2020

Schrödinger, Inc., whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced it will present data from its preclinical MALT1 inhibitor program at the 62nd American Society of Hematology Annual Meeting and Exposition to be held virtually December 5-8, 2020.
Schrödinger to Host Third Quarter 2020 Financial Results Conference Call and Webcast

11/5/2020

Schrödinger, whose physics-based software platform is transforming the way therapeutics and materials are discovered, announced it will host a conference call and webcast on Thursday, November 12, 2020 at 8:30 a.m. ET to discuss third quarter 2020 financial results and provide a general business update.
Schrödinger to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

9/8/2020

Schrödinger, whose physics-based software platform enables discovery of high-quality, novel molecules for therapeutics and materials, announced that members of the management team will participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference at 12:30 p.m. ET on Tuesday, September 15, 2020.
Schrödinger Announces Closing of Public Offering - Aug 17, 2020

8/17/2020

Schrödinger, Inc., whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, announced the closing of its underwritten public offering of 5,750,000 shares of its common stock at a public offering price of $66.00 per share.
Schrödinger Announces Pricing of Public Offering - Aug 13, 2020

8/13/2020

Schrödinger, Inc., whose differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications, announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $66.00 per share.

First
1
2
3
4
Next
Last